Intelligence · Clinical Pipeline
Phase II Pipeline Programs
Proof-of-concept and dose-finding clinical programs in Phase II development.
- Programs
- 7,238
Quick answer
NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.
Top sponsors
- Chinese Academy of 432 programs
- BRIGHT MINDS BIOSCIENCES 393 programs
- First People's Hospital 375 programs
- United Therapeutics Europe 336 programs
- Takeda 335 programs
- Anaxis Pharma 223 programs
- George Institute for 187 programs
- Regeneron UK 176 programs
- Teva Pharma 126 programs
- Novartis India 121 programs
- Telethon Foundation 119 programs
- Disc Medicine 106 programs
-
Neratinib
PUMA BIOTECHNOLOGY, INC.
GastroEsophageal Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
HER2 Amplified Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
HER2-positive Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Metastatic Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Advanced Breast Cancer
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
8 trials -
NestaCell®
Vera Therapeutics
COVID-19 Pneumonia
1 trial -
Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive
United Therapeutics Europe Ltd
Contraception
1 trial -
Neu2000KWL
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stroke
1 trial -
Neulasta 6 mg solution for injection
Istituto Gentili S.r.l.
Severe chronic neutropenia (SCN)
1 trial -
NeuroEPO
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Parkinson Disease
1 trial -
NicVAX
BRIGHT MINDS BIOSCIENCES INC.
Smoking Cessation
1 trial -
NicVAX conjugate vaccine
BRIGHT MINDS BIOSCIENCES INC.
Smoking Cessation
1 trial -
Nicotine 0 mg/mL
BRIGHT MINDS BIOSCIENCES INC.
Nicotine
1 trial -
Nicotine Patch
BRIGHT MINDS BIOSCIENCES INC.
Tobacco Use Disorder
2 trials -
Nicotine gum and lozenge
BRIGHT MINDS BIOSCIENCES INC.
Nicotine Dependence
1 trial -
Nicotine replacement
BRIGHT MINDS BIOSCIENCES INC.
Cardiovascular Disease
1 trial -
Nilotinib followed by treatment-free
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
1 trial -
Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal groups A, C, W-135 and Y conjugate vaccine, Prevenar 13 suspension for injection pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Rotarix oral suspension in pre-filled oral applicator Rotavirus vaccine, live, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IP
GlaxoSmithKline
Infections, Meningococcal
1 trial -
Nimodipine
BRIGHT MINDS BIOSCIENCES INC.
Cocaine-Related Disorders
1 trial -
Nimotuzumab
Chinese University of Hong Kong
Esophageal Cancer
1 trial -
Nimotuzumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Nimotuzumab
The First People's Hospital of Lianyungang
Esophageal Neoplasms
1 trial -
Nimotuzumab + SHR-1210
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Nimotuzumab combined with chemoradiotherapy
The First People's Hospital of Lianyungang
Pancreatic Cancer Non-resectable
1 trial -
Ninerafaxstat, Tablet, identical in appearance to ninerafaxstat tablets
Lacuna Pharma Pty Ltd
Non-obstructive hypertrophic cardiomyopathy
1 trial -
Ninlaro
Takeda
Immune Thrombocytopenia
1 trial -
Nintedanib,Dextromethorphan
The First People's Hospital of Lianyungang
Idiopathic Pulmonary Fibrosis (IPF)
1 trial -
Niraparib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ovarian Cancer
1 trial -
Niraparib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
1 trial -
Niraparib
Takeda
Ovarian Cancer
2 trials -
Niraparib
Takeda
Efficacy
1 trial -
Niraparib-Bevacizumab
Takeda
Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
1 trial -
Nitric Oxide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pressure Ulcer
1 trial -
Nitrofurazone Group 1
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Amyotrophic Lateral Sclerosis
1 trial -
Nitrous oxide
BRIGHT MINDS BIOSCIENCES INC.
Opioid-Related Disorders
1 trial -
Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab
Bristol-Myers Squibb Australia Pty Ltd
Neoplasms by site
1 trial -
Nivolumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Advanced Biliary Tract Cancer(BTC)
1 trial -
Nivolumab
Mereo BioPharma Group plc
Ovarian Cancer
1 trial -
Nivolumab
Bristol-Myers Squibb
Hepatocellular Carcinoma
1 trial -
Nivolumab
United Therapeutics Europe Ltd
Metastatic Uveal Melanoma
1 trial -
Nivolumab
Nektar Therapeutics UK Limited
Ependymoma
1 trial -
Nivolumab
Takeda
Relapsed Multiple Myeloma
1 trial -
Nivolumab
Bristol-Myers Squibb
Prostate Cancer
1 trial -
Nivolumab
Adaptive Biotechnologies Corp
Bladder Cancer
1 trial -
Nivolumab
Atrium Therapeutics
Multiple Myeloma
1 trial -
Nivolumab & Ipilimumab
The First People's Hospital of Lianyungang
Lung Cancer - Non Small Cell
1 trial -
Nivolumab Injection [Opdivo]
The First People's Hospital of Lianyungang
Neoplasms
1 trial
Frequently asked questions
How many Phase II pipeline programs are in the directory?
7,238 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.
Data attribution: Data sources · All pipeline programs